Skip to main content

OrbiMed Advisors LLC's Form 4 filing

Shattuck Labs, Inc. (STTK) · filed Jun 15, 2026

Accession no.
0000947871-26-000625
Filed
Jun 15, 2026, 6:12 PM ET
Trade date
Jun 11, 2026
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 2 derivative transactions. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
OrbiMed Advisors LLCCIK 0001055951Director
OrbiMed Genesis GP LLCCIK 0001808744Director
OrbiMed Capital GP IX LLCCIK 0001920574Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

This filing has no transactions of this kind.

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 11, 2026Common StockPPurchaseAcquired+1,041,667–F1–26,519,541IndirectDuplicate filing
Jun 11, 2026Common StockPPurchaseAcquired+208,333–F1–5,303,908IndirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

On June 9, 2026, the Issuer announced a public offering of an aggregate of 10,879,376 shares of common stock ("Shares") at a price of $4.00 per Share and, in lieu of Shares to certain investors, pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 7,870,624 Shares at a price of $3.9999 per Pre-Funded Warrant. The Pre-Funded Warrant have an exercise price of $0.0001 per share and are exercisable at any time after the date of issuance. The public offering closed on June 11, 2026.

Referenced by the price of 2 transactions in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)